A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Increases in serum prolactin concentrations after administration of risperidone have been attributed, by some, to the availability of paliperidone in plasma. This double-blind, randomized, parallel-group study in patients with schizophrenia compared serum prolactin concentrations following the administration of paliperidone extended-release and risperidone immediate-release tablets. At steady state, the doses administered resulted in a similar exposure to paliperidone and the pharmacologically active fraction of risperidone (i.e. risperidone + paliperidone), respectively. Eligible patients were randomized to either paliperidone extended-release 12 mg on days 1—6 or risperidone immediate-release 2 mg on day 1 and 4 mg on days 2—6. Mean serum prolactin concentrations increased on day 1 (C max : 71.8 ng/ml and 89.7 ng/ml reached at 6.5 hours and 2.6 hours for paliperidone extended-release and risperidone immediate-release, respectively). On day 6, serum prolactin concentration—time profiles were similar for both treatments, with overall higher serum prolactin concentrations than on day 1 (AUC 0—24 h : 1389 and 842 ng h/ml, and 1306 and 741 ng.h/ml on day 6 and day 1 for paliperidone extended-release and risperidone immediate-release, respectively). These results indicate that paliperidone extended-release 12 mg and risperidone immediate-release 4 mg, administered over a period of 6 days, lead to similar elevations in serum prolactin concentrations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This discrepancy between brexpiprazole concentration elevation and prolactin level elevation by multiple doses of drugs did not correlate with the trend seen with other dopamine D2 receptor antagonist antipsychotics.12”
From Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia (2018) · cites this paper as [12]
In the citing paper
“Antipsychotics have a blocking effect on the dopamine D2 receptor and therefore can elevate the secretion of prolactin.11, 12”
From Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia (2018) · cites this paper as [12]
Citations
Cites
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167 · cited 1×
“Paliperidone is a novel antipsychotic agent that acts as a central dopamine D2 and serotonin 5-HT2A antagonist, a mode of action common to many atypical antipsychotic agents (Megens and Awouters, 1994; Schotte et al., 1996; Karlsson et al., 2006).”
BackgroundA Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034 · cited 2×
“, 1993), an established atypical antipsychotic (Marder et al., 1997; Bouchard et al., 2000; Csernansky et al., 2002; Davis et al., 2003).”
BackgroundMarder, S. R., Davis, J. M., & Chouinard, G. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1205 · Cited by 759 · cited 2×
“, 1993), an established atypical antipsychotic (Marder et al., 1997; Bouchard et al., 2000; Csernansky et al., 2002; Davis et al., 2003).”
BackgroundCsernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605 · cited 2×
“, 1993), an established atypical antipsychotic (Marder et al., 1997; Bouchard et al., 2000; Csernansky et al., 2002; Davis et al., 2003).”
BackgroundOlanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Beasley, C. M., Sanger, T., Satterlee, W., Tollefson, G., Tran, P., & Hamilton, S. (1996) · Psychopharmacology · doi:10.1007/bf02245617 · Cited by 390 · cited 2×
“However, the frequency and degree of prolactin elevation has been found to be reduced with some of the more recently introduced atypical antipsychotics such as aripiprazole, clozapine, olanzapine, quetiapine and ziprasidone (Kane et al., 1981; Beasley et al., 1996; Daniel and Copeland, 2000), but not with amisulpride…”
BackgroundProlactin Levels and Adverse Events in Patients Treated with Risperidone
Kleinberg, D. L., Davis, J. M., de Coster, R., Van Baelen, B., & Brecher, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00011 · Cited by 307 · cited 1×
“Long-term prospective studies of risperidone IR have shown no clear association between elevated serum prolactin concentrations and the occurrence of potentially prolactin-related AEs when patients were followed up for a period of up to five years (Kleinberg et al., 1999; Eberhard et al., 2007).”
BackgroundAbsorption, metabolism, and excretion of risperidone in humans.
Mannens, G., Huang, M. L., Meuldermans, W., Hendrickx, J., Woestenborghs, R., & Heykants, J. (1993) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08211-x · Cited by 261 · cited 3×
“Paliperidone is the active metabolite of risperidone (RISPERDAL , Janssen Pharmaceuticals, Titusville, NJ, USA) (Mannens et al., 1993), an established atypical antipsychotic (Marder et al.”
BackgroundVolavka, J., Czobor, P., Cooper, T. B., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., & Lieberman, J. A. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0109 · Cited by 201 · cited 2×
“, 1996; Daniel and Copeland, 2000), but not with amisulpride or risperidone (Kinon et al., 2003; Volavka et al., 2004; Melkersson, 2005).”
BackgroundPharmacologic approach to management of agitation associated with dementia.
Heykants, J., Huang, M. L., Mannens, G., Meuldermans, W., Snoeck, E., Beijsterveldt, L. V., Peer, A. V., & Woestenborghs, R. (1994) · PubMed · Cited by 200
Kinon, B. J., Gilmore, J. A., Liu, H., & Halbreich, U. M. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00128-2 · Cited by 161 · cited 2×
“, 1996; Daniel and Copeland, 2000), but not with amisulpride or risperidone (Kinon et al., 2003; Volavka et al., 2004; Melkersson, 2005).”
BackgroundPredominant Role of the 9-Hydroxy Metabolite of Risperidone in Elevating Blood Prolactin Levels
Knegtering, R., Baselmans, P., Castelein, S., Bosker, F., Bruggeman, R., & van den Bosch, R. J. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.1010 · Cited by 150 · cited 10×
“…suggested a relatively stronger correlation of serum prolactin concentrations with the plasma concentrations of paliperidone than with risperidone plasma concentrations after administration of risperidone IR (Knegtering et al., 2005; Melkersson, 2006; Eberhard et al., 2007; Troost et al., 2007).”
BackgroundResultInfluentialCircadian Periodicity of Serum Prolactin Concentration in Man
Nokin, J., Vekemans, M., L'Hermite, M., & Robyn, C. (1972) · BMJ · doi:10.1136/bmj.3.5826.561 · Cited by 140 · cited 1×
“Prolactin secretion from the pituitary gland is subject to a circadian rhythm, which may help to explain this phenomenon (Nokin et al., 1972).”
BackgroundDossenbach, M., Dyachkova, Y., Pirildar, S., Anders, M., Khalil, A., Araszkiewicz, A., Shakhnovich, T., Akram, A., Pecenak, J., McBride, M., et al. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.12.005 · Cited by 121 · cited 2×
“Some observational studies suggest that antipsychotic medications can differ with respect to treatment-emergent sexual dysfunction, with antipsychotics that are known to increase serum prolactin to a greater extent such as haloperidol and risperidone being more frequently associated with sexual dysfunction than other…”
BackgroundMelkersson, K. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0614 · Cited by 98 · cited 3×
“, 1996; Daniel and Copeland, 2000), but not with amisulpride or risperidone (Kinon et al., 2003; Volavka et al., 2004; Melkersson, 2005).”
BackgroundClozapine: Plasma levels and prolactin response
Kane, J. M., Cooper, T. B., Sachar, E. J., Halpern, F. S., & Bailine, S. H. (1981) · Psychopharmacology · doi:10.1007/bf00429215 · Cited by 93 · cited 2×
“…reduced with some of the more recently introduced atypical antipsychotics such as aripiprazole, clozapine, olanzapine, quetiapine and ziprasidone (Kane et al., 1981; Beasley et al., 1996; Daniel and Copeland, 2000), but not with amisulpride or risperidone (Kinon et al., 2003; Volavka et al.,…”
BackgroundRemmerie, B. M. M., Sips, L., de Vries, R., de Jong, J., Schothuis, A. M., Hooijschuur, E. W. J., & van de Merbel, N. C. (2002) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00715-8 · Cited by 86 · cited 1×
“Plasma concentrations of paliperidone and risperidone were determined using a validated liquid chromatography coupled with mass spectrometry/mass spectrometry, based on a published assay (Remmerie et al., 2003).”
MethodSelf-citationMelkersson, K. I. (2006) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.811 · Cited by 70 · cited 6×
“…suggested a relatively stronger correlation of serum prolactin concentrations with the plasma concentrations of paliperidone than with risperidone plasma concentrations after administration of risperidone IR (Knegtering et al., 2005; Melkersson, 2006; Eberhard et al., 2007; Troost et al., 2007).”
BackgroundInfluentialPlasma Prolactin and Central D2 Receptor Occupancy in Antipsychotic Drug-Treated Patients
Nordstrom, A.-L., & Farde, L. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00010 · Cited by 69 · cited 1×
“Dopamine D2-receptor antagonists, such as the conventional antipsychotic agents, have been associated with increases in serum prolactin concentrations (Nordstrom and Farde, 1998).”
BackgroundProlactin Release in Children Treated With Risperidone
Troost, P. W., Lahuis, B., Hermans, M. H. A., Buitelaar, J. K., van Engeland, H., Scahill, L. D., Minderaa, R. B., & Hoekstra, P. J. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802e68d5 · Cited by 61 · cited 11×
“…suggested a relatively stronger correlation of serum prolactin concentrations with the plasma concentrations of paliperidone than with risperidone plasma concentrations after administration of risperidone IR (Knegtering et al., 2005; Melkersson, 2006; Eberhard et al., 2007; Troost et al., 2007).”
BackgroundResultInfluentialProlactin level during 5 years of risperidone treatment in patients with psychotic disorders
Eberhard, J., Lindström, E., Holstad, M., & Levander, S. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00897.x · Cited by 57 · cited 11×
“…suggested a relatively stronger correlation of serum prolactin concentrations with the plasma concentrations of paliperidone than with risperidone plasma concentrations after administration of risperidone IR (Knegtering et al., 2005; Melkersson, 2006; Eberhard et al., 2007; Troost et al., 2007).”
BackgroundResultInfluentialBouchard, R.-H., Mérette, C., Pourcher, E., Demers, M., Villeneuve, J., Roy‐Gagnon, M., Gauthier, Y., Cliche, D., Labelle, A., Filteau, M., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00002 · Cited by 47 · cited 2×
“, 1993), an established atypical antipsychotic (Marder et al., 1997; Bouchard et al., 2000; Csernansky et al., 2002; Davis et al., 2003).”
BackgroundZiprasidone: comprehensive overview and clinical use of a novel antipsychotic
Daniel, D. G., & Flynn, L. C. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.4.819 · Cited by 37 · cited 2×
“However, the frequency and degree of prolactin elevation has been found to be reduced with some of the more recently introduced atypical antipsychotics such as aripiprazole, clozapine, olanzapine, quetiapine and ziprasidone (Kane et al., 1981; Beasley et al., 1996; Daniel and Copeland, 2000), but not with amisulpride…”
BackgroundKARLSSON, P., DENCKER, E., NYBERG, S., MANNAERT, E., BOOM, S., TALLURI, K., ROSSENU, S., ERIKSSON, B., EERDEKENS, M., & FARDE, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.12.265 · Cited by 37 · cited 1×
“Paliperidone is a novel antipsychotic agent that acts as a central dopamine D2 and serotonin 5-HT2A antagonist, a mode of action common to many atypical antipsychotic agents (Megens and Awouters, 1994; Schotte et al., 1996; Karlsson et al., 2006).”
BackgroundSelf-citationMegens, A. A. H. P., & Awouters, F. H. L. (1994) · Drug Development Research · doi:10.1002/ddr.430330403 · Cited by 28
Rossenu, S., Cleton, A., Talluri, K., Francetić, I., Canuso, C. M., Remmerie, B. M. M., Janssens, L., Eerdekens, M., & Boom, S. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.373 · Cited by 2 · cited 1×
“The primary objective of the study was a non-inferiority comparison of paliperidone ER and risperidone IR for orthostatic tolerability, the results of which are reported elsewhere (Rossenu et al., 2008).”
ResultSelf-citation
Research works printed but not linked: 3
- Cleton A., 2007, Clin Pharm Rev, 81, S62
- Heykants J., 1994, J Clin Psychiatry, 55, 13
- Invega Prescribing Information, 2006, Janssen Pharmaceuticals
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
“For oral drugs delivered in extended release formulations like venlafaxine, methylphenidate, paliperidone [110] or quetiapine [356], special attention has to be given to the time of drug intake for correct interpretation (see ▶Table 4).”
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0037-1600991 · Cited by 325
“For oral drugs delivered in extended release formulations like venlafaxine, methylphenidate, paliperidone [110] or quetiapine [356], special attention has to be given to the time of drug intake for correct interpretation (see ▶Table 4).”
Peuskens, J., Pani, L., Detraux, J., & De Hert, M. (2014) · CNS Drugs · doi:10.1007/s40263-014-0157-3 · Cited by 350
“similar PRL pharmacokinetic profiles (maximum plasma concentration, Cmax and area under the curve, AUC) when subjects received the highest recommended dose of paliperidone ER (12 mg/day) compared with an average dose of risperidone (4 mg/day) [283].”
BackgroundMalik, P., Kemmler, G., Hummer, M., Riecher-Roessler, A., Kahn, R. S., & Fleischhacker, W. W. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182199bcc · Cited by 115
“Conventional antipsychotics induce hyperprolactinemia more often than second-generation antipsychotics, except for amisulpride, risperidone,(12) and paliperidone.(13) In addition, peripheral effects of antipsychotics on the sexual target organs need to be taken into account.”
BackgroundSexual Dysfunction Related to Psychotropic Drugs: A Critical Review Part II: Antipsychotics
La Torre, A., Conca, A., Duffy, D., Giupponi, G., Pompili, M., & Grözinger, M. (2013) · Pharmacopsychiatry · doi:10.1055/s-0033-1347177 · Cited by 109
Metadata
- Authors
- Berwaerts, J., Cleton, A., Rossenu, S., Talluri, K., Remmerie, B., Janssens, L., Boom, S., Kramer, M., & Eerdekens, M.
- Affiliations
- Johnson & Johnson (United States) (US)
- Johnson & Johnson Pharmaceutical Research and Development, Beerse, Belgium
- Janssen Research & Development (United States) (US)
- Johnson & Johnson Pharmaceutical Research and Development Early Development, San Diego, CA, USA
- Corresponding author
- Berwaerts, Joris
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2009-10-13
- Volume
- 24
- Issue
- 7
- Pages
- 1011-1018
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1965085115
- Cited by
- 49
- References
- 25
- Citations by year
- 2026: 2 · 2025: 1 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2018: 1 · 2017: 4 · 2016: 3 · 2015: 2 · 2014: 6 · 2013: 9 · 2012: 6
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- serum prolactin, paliperidone extended-release, risperidone, schizophrenia, antipsychotic adverse effects, drug exposure, pharmacokinetics, prolactin elevation, atypical antipsychotics
- MeSH terms
- Paliperidone Palmitate, Adolescent, Adult, Delayed-Action Preparations, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypotension, Orthostatic, Isoxazoles, Male, Middle Aged, Prolactin, Psychiatric Status Rating Scales, Pyrimidines, Schizophrenia, Antipsychotic Agents, Risperidone, Area Under Curve, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.